Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 9/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 4/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18689716 | 0.75 | DRD2 (0.44) | — | |
| SCHEMBL14077925 | 0.74 | S1PR2 (0.41) | S1PR2 | |
| SCHEMBL3387388 | 0.73 | MC4R (0.40) | MC4RRORC | |
| SCHEMBL3386011 | 0.73 | KCNN4 (0.39) | — | |
| SCHEMBL1010168 | 0.73 | GPR119 (0.48) | S1PR2GPR119 | |
| SCHEMBL5188937 | 0.71 | S1PR2 (0.39) | S1PR2 | |
| SCHEMBL4150693 | 0.71 | OPRM1 (0.34) | CNR2 | |
| SCHEMBL3772170 | 0.69 | OPRL1 (0.38) | MC4R | |
| SCHEMBL17350664 | 0.68 | HSD11B1 (0.35) | — | |
| SCHEMBL1576654 | 0.68 | CYP1A2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501777-B2 | 1-ethyl-4-[3-fluoro-5-(methylsulfonyl)phenyl]piperidine; central nervous system disorders, Parkinson's disease, Parkinsonism, dyskinesias, including L-DOPA induced dyskinesias, dystonias, tics, tremor, Huntington disease | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2013-08-06 | — | — | US | disclosed |
| US-20080234321-A1 | 3,5-Disubstituted Phenyl-Piperidines as Modulators of Dopamine Neurotransmission | SANIONA AB (DK) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234321-A1 | 3,5-Disubstituted Phenyl-Piperidines as Modulators of Dopamine Neurotransmission | SLC6A3, DRD2, DRD3 | CNR2 70/4885S1PR2 547/4885NR1H2 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.